NCT07234058
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07234058
Title Trial Assessing Fianlimab Plus Cemiplimab Plus Chemotherapy or Cemiplimab Plus Chemotherapy in Patients With Pleural Mesothelioma (LAG-MAPS)
Acronym LAG-MAPS
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Intergroupe Francophone de Cancerologie Thoracique
Indications
Therapies
Age Groups: senior | adult
Covered Countries FRA


No variant requirements are available.